Acumen Pharmaceuticals (ABOS) Common Equity (2020 - 2026)

Acumen Pharmaceuticals' Common Equity history runs 7 years deep, the most recent figure standing at $87.5 million for Q1 2026.

• In Q1 2026, Common Equity fell 43.75% year-over-year to $87.5 million; the TTM figure through Mar 2026 stood at $87.5 million (down 43.75% YoY), while the FY2025 annual figure was $70.4 million, down 61.26% from the prior year.
• Common Equity came in at $87.5 million for Q1 2026 at Acumen Pharmaceuticals, up from $70.4 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $280.3 million in Q3 2023 to a low of $70.4 million in Q4 2025.
• A 5-year average of $184.2 million and a median of $188.8 million in 2022 frame the typical range for Common Equity.
• Across the five-year window, Common Equity jumped 575.32% in 2022 and sank 61.26% in 2025, its largest moves.
• Acumen Pharmaceuticals' Common Equity stood at $188.8 million in 2022, then jumped by 41.42% to $267.0 million in 2023, then sank by 31.9% to $181.8 million in 2024, then tumbled by 61.26% to $70.4 million in 2025, then gained by 24.2% to $87.5 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $87.5 million, $70.4 million, and $93.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison